Previous Close | 41.88 |
Open | 41.84 |
Bid | 41.48 x 48300 |
Ask | 41.49 x 51100 |
Day's Range | 41.35 - 41.90 |
52 Week Range | 33.75 - 44.81 |
Volume | |
Avg. Volume | 628,265 |
Market Cap | 9.203B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 29.63 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.18 (2.94%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | N/A |
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA reviewGermantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE